Skip to Content

FDA Sends Alcon Letter on Travatan Z About Covention Graphic

ROCKVILLE, Md., Oct. 21, 2010--The FDA has posted on its web site a letter sent to Alcon Research about a covention graphic the company submitted for its eye care drug Travatan Z. According to the agency, the convention graphic is misleading "because it broadens the indication for Travatan Z and makes unsubstantiated superiority claims." 

DDMAC Letter

Promotional Material

Posted: October 2010